CDMO News
AtomVie and Radiopharm Ventures Collaborate on 177Lu-BetaBart Development
AtomVie Global Radiopharma, a radiopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced a partnership with Radiopharm Ventures (RV) to develop and manufacture 177Lu-BetaBart. This targeted radioantibody focuses on B7-H3, an immune checkpoint molecule prevalent in multiple solid tumours. The